187 related articles for article (PubMed ID: 33942169)
1. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
[TBL] [Abstract][Full Text] [Related]
2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
3. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
Varkhede N; Forrest ML
J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
[TBL] [Abstract][Full Text] [Related]
5. A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins.
Gill KL; Gardner I; Li L; Jamei M
AAPS J; 2016 Jan; 18(1):156-70. PubMed ID: 26408308
[TBL] [Abstract][Full Text] [Related]
6. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
7. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
Li Z; Li Y; Chang HP; Yu X; Shah DK
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
[TBL] [Abstract][Full Text] [Related]
8. Effect of Size on Solid Tumor Disposition of Protein Therapeutics.
Li Z; Li Y; Chang HP; Chang HY; Guo L; Shah DK
Drug Metab Dispos; 2019 Oct; 47(10):1136-1145. PubMed ID: 31387870
[TBL] [Abstract][Full Text] [Related]
9. Influence of Molecular size on the clearance of antibody fragments.
Li Z; Krippendorff BF; Shah DK
Pharm Res; 2017 Oct; 34(10):2131-2141. PubMed ID: 28681164
[TBL] [Abstract][Full Text] [Related]
10. Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Model Development.
Zheng F; Hou P; Corpstein CD; Xing L; Li T
Pharm Res; 2021 Apr; 38(4):607-624. PubMed ID: 33811278
[TBL] [Abstract][Full Text] [Related]
11. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.
Zhao L; Ji P; Li Z; Roy P; Sahajwalla CG
J Clin Pharmacol; 2013 Mar; 53(3):314-25. PubMed ID: 23426855
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties.
Hu S; Datta-Mannan A; D'Argenio DZ
AAPS J; 2022 Dec; 25(1):5. PubMed ID: 36456779
[TBL] [Abstract][Full Text] [Related]
13. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins.
Zou P; Wang F; Wang J; Lu Y; Tran D; Seo SK
J Control Release; 2021 Aug; 336():310-321. PubMed ID: 34186147
[TBL] [Abstract][Full Text] [Related]
14. Multiscale pharmacokinetic modeling of systemic exposure of subcutaneously injected biotherapeutics.
Zheng F; Hou P; Corpstein CD; Park K; Li T
J Control Release; 2021 Sep; 337():407-416. PubMed ID: 34324897
[TBL] [Abstract][Full Text] [Related]
15. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
16. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Shah DK; Balthasar JP
Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
[TBL] [Abstract][Full Text] [Related]
17. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
Bussing D; K Shah D
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
[TBL] [Abstract][Full Text] [Related]
18. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
J Pharmacokinet Pharmacodyn; 2024 Feb; ():. PubMed ID: 38400996
[TBL] [Abstract][Full Text] [Related]
19. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
